China (Mainland)
Premiumsupplier
High Quality Ticagrelor CAS NO.274693-27-5
- Min.Order: 10 Gram
- Payment Terms: T/T,
- Product Details
Keywords
- Ticagrelor
- Ticagrelor powder
- cas 274693-27-5
Quick Details
- ProName: High Quality Ticagrelor
- CasNo: 274693-27-5
- Molecular Formula: C22H30N4O
- Appearance: white powder
- Application: approved for use in the European Union...
- DeliveryTime: immediately
- PackAge: aluminum foil bag
- Port: HK, Shanghai, Shenzhen
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: cool and dry place
- Transportation: email: wonda-chem@outlook.com
- LimitNum: 10 Gram
Superiority
1.high quality:
quality is life. quality is the most important element for all goods. we have a lab doing research in wuhan china. hplc and nmr is available if needed.
2.reasonable price:
we provide high quality products with competitive price in china. all customers are welcomed to send us inquiries and get quotation.
3.low moq:
no worry about the low moq, our moq is 1 gram or even lower.
4.good service.
fast response. we promise to reply within 24 hours including holidays and send quotation sheet and other documents within 48 hours.
5. fast shipping and secure courier.
we promise to send out products and provide tracking number within 3 working days. and we send via different couriers based on different destination countries. we usually use nl post, hk post, germany post, eub, etk, etc.
Details
Product name: Ticagrelor
Appearance: white powder
CAS NO.: 274693-27-5
Molecular formula: C23H28F2N6O4S
Molecular weight: 522.568
Ticagrelor is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.The drug was approved by the US Food and Drug Administration on July 20, 2011.
Ticagrelor is an antagonist of the P2Y12 receptor.
Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor, which is the main receptor responsible for ADP-induced platelet aggregation.
Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world’s first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.
|
Item |
Specifications |
|
Appearance |
White or whitish crystalline powder |
|
Identification |
IR |
|
HPLC |
|
|
Loss on drying |
≤0.5% |
|
MP ref. |
About 146~153 c degree |
|
Optical rotation |
Methanol C=1 -40- -60 0° |
|
Residue on Ignition |
≤0.5% |
|
Heavy metal |
<20ppm |
|
Related substance |
Single impurity: ≤0.5% |
|
Total impurities: ≤1.0% |
|
|
residual Solvent |
Methanol<3000 |
|
Ethanol<5000 |
|
|
Acetone<5000 |
|
|
N(CH3CH2)3<300 |
|
|
Assay(HPLC) |
≥99.0% |
|
Assay by titration |
99~101% |
